Skip to main content
 Home
  • Dansk
  • English

Servicemenu

  • News
  • Events
    • Previous Events
  • Themes
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design

Hovedmenu

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Hovedmenu - mobil

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
        • Personal Data Policy for Recruitment
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Servicemenu - mobil

  • News
  • Events
    • Previous Events
  • Themes
  • Analyser
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design
  • Dansk
  • English

Breadcrumb

  1. Home
  2. Business Activities
  3. Lundbeckfonden BioCapital
  4. NMD Pharma

NMD Pharma

NMD Pharma is a clinical stage biotech company developing treatments for neuromuscular diseases.

NMD develops small molecule inhibitors of skeletal muscle specific ion channels to treat neuromuscular indications, improve muscle function and support essential human behavior. The approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Related news about NMD Pharma

  • NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
  • NMD Pharma Raises €35 Million in a new Financing
  • NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
  • NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
  • NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Logo
NMD Pharma's website

Lundbeckfonden BioCapital

Invested
2016
Location

Aarhus, Denmark

Contact

Christian Elling

Christian Elling

Managing Partner Lundbeckfonden BioCapital

cee@lundbeckfonden.com
Mobile

+45 2062 1276

Footer logo
The Lundbeck Foundation annually distributes more than DKK 500 mio. to Danish-based healthcare science research, primarily with a focus on the brain.

Lundbeckfonden
Scherfigsvej 7
2100 København Ø

CVR
11814913

Links

  • Cookie-Policy
  • Disclaimer & Privacy
  • History and Statutes
  • Our Strategy
  • Events
  • Contact
  • Jobs
Follow us
Facebook
Twitter
LinkedIn
Youtube